Completed PHASE2 INTERVENTIONAL 1-arm NCT00023322

Pegylated Interferon to Treat Chronic Hepatitis D

Treatment of Chronic Delta Hepatitis With Pegylated Interferon

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Updated 6 times since 2017 Last updated: Jul 9, 2013 Started: Aug 31, 2001 Primary completion: May 31, 2012 Completion: Oct 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hepatitis D and is currently completed. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) leads this study, which shows 6 recorded versions since 2001 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States